BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
BCI
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 24, 2026
See today's BioWorld
Home
» Medivation Rocked by Dimebon Miss in Late-Stage AD Study
To read the full story,
subscribe
or
sign in
.
Medivation Rocked by Dimebon Miss in Late-Stage AD Study
March 4, 2010
By
Catherine Hollingsworth
Shares in Medivation Inc. fell 67.5 percent Wednesday on news that its Phase III trials of Alzheimer's drug candidate Dimebon missed all of the study's stated goals, smashing some high hopes on Wall Street. (BioWorld Today)
BioWorld
